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Introduction
Drug-drug interactions (DDIs) can result when one drug alters the pharmacokinetics of another drug or its metabolites. According to the new FDA Draft Guidance (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u cm292362.pdf), the pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug's safety and effectiveness. Therefore, predicting clinically significant drug interactions during drug development is essential for the pharmaceutical industry and regulatory agencies.
The large number of clinically significant DDIs due to the inhibition of cytochrome P450 (CYP) substrate metabolism and the availability of in vitro, in vivo, and clinical methods for assessing CYP DDIs have made this a logical starting point for the development and validation of techniques to predict clinically significant DDIs.
There exists a broad consensus as to the common principles underlying prediction of the magnitude of an in vivo DDI from in vitro data. The increase in the area under the plasma concentration-time curve (AUC) of a substrate when co-administered in the presence of a reversible inhibitor of the substrate's elimination pathway is a function of the ratio of inhibitor concentration ([I] ) to inhibition constant (K i ) (Ito et al., 1998; Shou, 2005; Brown et al., 2006; Obach et al., 2006; Einolf, 2007) . A similar model involving K I (concentration of inhibitor required to achieve half-maximal inactivation) and k inact (maximal rate constant of enzyme inactivation) for DDIs associated with irreversible (mechanism-based) inhibitors has also been proposed (Obach et al., 2007) . In addition, researchers have incorporated the fraction of substrate clearance mediated by the inhibited enzyme (f mCYP ), the plasma protein binding of the inhibitor This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on May 4, 2012 as DOI: 10.1124 at ASPET Journals on April 15, 2017 dmd.aspetjournals.org Downloaded from (Shardlow et al., 2011) , and fraction of absorbed substrate dose escaping gut metabolism by CYP3A (F G ) (Galetin et al., 2008) to improve predictions for certain drug classes.
Although in vitro-based models can quantitatively predict many in vivo DDIs with acceptable accuracy, the application of this model to the prediction of DDIs associated with CYP inhibitors that have inhibitory metabolites has not been successful (Yeung et al., 2011; McDonald et al., 2012) . The prediction accuracy of in vitro models may be improved to some extent when data pertaining to metabolites were included in the model; however, prediction accuracy (35-188%) was still unsatisfactory for DDIs associated with ten typical inhibitors that have inhibitory metabolites (Yeung et al., 2011) . Another recent study found that prediction accuracy decreased when more inhibitory metabolites of amiodarone were taken into account (McDonald et al., 2012) . A novel approach, in vivo information-guided prediction (IVIP), was recently introduced for CYP3A-and CYP2D6-mediated drug interactions (Ohno et al., 2007; Tod et al., 2011) . This model relies primarily on in vivo data and uses two characteristic parameters: one for the substrate, and the other for the inhibitor. This model has the potential to take into account inhibitory metabolites, different mechanisms of inhibition, and intestinal inhibition. Although information on the inhibitory metabolites can also be incorporated into an in vitro-based model, the IVIP approach has certain advantages when compared with in vitro-based methods.
Validation of the IVIP approach for the prediction of DDIs mediated by other CYP450 enzymes or the effects of inhibitory metabolites on DDIs is still lacking, due to the paucity of available data. Therefore, the aims of this study are to extend the IVIP approach to CYP2C9-mediated interactions, and to validate the modified IVIP approach for prediction of DDIs associated with inhibitors that have inhibitory metabolites.
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Materials and Methods
Extending the IVIP approach to CYP2C9-mediated interactions. Medline, PubMed, and Embase databases (from 1975 (from until December 31, 2011 were searched using the terms "CYP2C9," "inhibition," and "pharmacokinetics". Citations within the retrieved articles were used to search for additional relevant studies. Studies were included if: (1) they were conducted in humans, (2) they provided the ratio between the AUC of the substrate when administered alone and when co-administered at the same dose with the inhibitor, (3) the dose of the inhibitor was within the therapeutic dose range, and (4) the inhibitor and substrate drugs were orally or intravenously administered to the subjects. Drug-drug interaction studies associated with herbal products, combination therapies, and oral contraceptives were excluded. Both reversible and irreversible inhibitors were included in the analysis.
An IVIP approach that has been previously described was modified and applied to the quantitative prediction of CYP2C9-mediated DDIs (Ohno et al., 2007; Tod et al., 2011) . This modeling framework utilizes two characteristic parameters: the contribution ratio (CR) defined as the contribution of the specific enzyme to the oral clearance or total clearance (intravenous administration) of the drug whose metabolism is inhibited (victim), and the apparent inhibition ratio (IR) of the inhibiting drug (perpetrator). If reasonable estimates of CR (0 ≤ CR ≤ 1) and IR (0 ≤ IR ≤ 1) can be determined, then the ratio of the AUC in the presence (AUC I ) and absence (AUC) of the inhibitor can be estimated using the following equation (Ohno et al., 2007; Hisaka et al., 2010; Tod et al., 2011) :
This article has not been copyedited and formatted. The final version may differ from this version. In contrast to the complex derivation by previous studies (Ohno et al., 2007; Tod et al., 2011 For the CYP2D6-and CYP3A-mediated DDIs, the CR values of most victim drugs can be estimated directly from in vivo data using the pharmacogenetic or drug interaction methods (Ohno et al., 2007; Tod et al., 2011) . The pharmacogenetic method (Tod et al., 2011) allows determining CR from equation 3, where AUC PM is the AUC in poor metabolizers and AUC EM is the AUC in extensive metabolizers.
Estimating CR using the interaction method (equation 4) is based on transformation of equation 1 using a known IR value of the inhibitor (IR was assumed to be 1.0 for very strong inhibitor), where AUC I is the AUC of the drug when the inhibitor is coadministered.
However, the IVIP approach developed for CYP2D6-and CYP3A-mediated DDIs cannot be directly extended to CYP2C9-mediated DDIs without modification. The CR values of CYP2C9
substrates cannot be reliably estimated by the pharmacogenetic method because relevant studies in CYP2C9 poor metabolizers are limited. Furthermore, the CR of most CYP2C9 substrates cannot be calculated by equation 4 due to the absence of IR data (e.g. The IR value can be assumed to be 1 for a very strong CYP inhibitor, but no strong inhibitor of CYP2C9 has been found according to the new FDA Draft Guidance and a recent study (Polasek et al., 2011) ).
Therefore, the CR of CYP2C9 substrates was estimated using equation 5; where f m is the contribution of CYP2C9 to hepatic clearance (estimated in vitro by CYP2C9-specific inhibitor or functional neutralizing antibody), and f h is the contribution of the hepatic clearance to the total clearance of the drug (estimated by the recovery of excreted CYP2C9 metabolites in urine, bile and feces).
The CR values of most CYP2C9 substrates were estimated by the extrapolation method (CR = f m ·f h ) using literature data. A learning set (learning set 1) was selected to calculate the IR of CYP2C9 inhibitors. Only the DDIs associated with typical CYP2C9 substrates (S-warfarin, tolbutamide, diclofenac, and phenytoin) were included in this learning set. results from multiple studies were available for a single combination of substrate and inhibitor (same dose of inhibitor was used in these studies).
Evaluation of the IVIP approach in predicting the DDI risks of various inhibitors with circulating inhibitory metabolites. The relevant data of clinical DDIs associated with CYP inhibitors that have inhibitory metabolites were mainly retrieved from a single recent report (Yeung et al., 2011) , which is based on the University of Washington Metabolism and Transport Drug Interaction Database (MTDI database: http://www.druginteractioninfo.org). Whenever available, additional data from the literature were included. In vivo DDI studies were included in our analysis only if they had been conducted with a reliable CYP probe. For CYP3A-and CYP2D6-mediated DDIs, only data from oral administration were included in the analysis. An algebraic mean of the AUC increase was used in the calculation when multiple studies were available for a single combination of victim drug and inhibitor (same dose of inhibitor was used in these studies).
Using the above retrieved data, in vivo DDIs associated with inhibitory metabolites were predicted by the fully validated IVIP approach. In order to avoid "self-prediction", the data in the learning set were not included in the validation set, and vice versa. The learning sets for CYP2D6-and CYP3A-mediated DDIs were selected according to the following criteria: (1) the dose of the inhibitor in the learning set is the same as in the validation set, (2) the regimens of the inhibitor in the learning set and the validation set are both multiple-dose or single-dose regimen, and (3) the victim drug is a known probe, or a substrate with a relatively high CR value.
These retrieved data were also used to predict in vivo DDIs by each of the in vitro-based methods. The steady-state concentrations [I] of the inhibitors were estimated in two ways; (1) total systemic C max , and 2) unbound hepatic inlet concentration (UHI) defined by equation 6, where k a is the absorption rate constant (0.03/min, an assumed average value (Obach et al., 2006) ), F a is the fraction absorbed (assumed to be 1), D is the dose of the inhibitor, Q h is the liver blood flow (1498 mL/min), and f u is the unbound fraction of drug in plasma. This equation assumes that metabolism of the inhibitor in the gut is negligible.
For reversible inhibitors of CYP2C9 and CYP2D6, equation 7 was used to predict the clinical DDI. The effect of multiple inhibitors was accounted for by summing the [I]/K i ratios (Yeung et al., 2011) . It should be pointed out that both f mCYP (in vitro-based model) and CR (IVIP model) indicate the contribution ratio of the target metabolizing enzyme to the clearance of a substrate drug after oral absorption or intravenous administration, so the same value is used in our analysis.
Predictions for reversible inhibitors of CYP3A used equation 8 and incorporated the contribution of gut metabolism, where F G is the fraction of absorbed substrate escaping gut metabolism by CYP3A. The concentration in the gut, [I] gut , was defined by equation 9, where Q g is the enterocytic blood flow (248 mL/min).
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Predictions for irreversible inhibitors of CYP3A used equation 10 with a k deg (hepatic) of 0.000321/min (Obach et al., 2007) , F G of the substrate and the degradation rate constant for CYP3A in the enterocyte [k deg (gut) = 0.000481/min (Obach et al., 2007) ].
Assessment of predictive performance. To assess the quantitative accuracy of each model, a prediction error was calculated from the difference between each predicted AUC ratio and the observed ratio. The prediction bias of each assumption was calculated as an average deviation (AD) of the predicted versus observed AUC ratios. The precision of each assumption was calculated as the root-mean-square error (RMSE). The observed and predicted DDIs were assigned as "positive" if AUC ratio was ≥ 1.25 or otherwise were termed as "negative." This threshold was selected to maximize our ability to make conservative decisions on the necessity for a clinical DDI study, and approximates the FDA standards for bioequivalence and weak inhibition (FDA Draft Guidance for Industry, 2012). The sensitivity and specificity of each prediction model was determined. Sensitivity is a measure of the ability of the prediction approach to successfully identify a positive DDI. The specificity of a prediction approach is defined as its ability to successfully identify a negative (AUC ratio < 1.25) or weak DDI (1.25 ≤ AUC ratio < 2.00).
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References for the DDI studies involving CYP2C9 that were used for the external validation are shown in Table 3 . A total of 19 AUC ratios were available. The relationship between the observed and predicted AUC ratios is plotted in Fig. 1A . All the points are inside the range of acceptable predictions (50% to 200%). The prediction accuracy of AUC I /AUC ranged from 70 to 125% (Fig. 1B) . The predictive sensitivity and specificity were both 93%. The predictive error and precision were −0.09 and 0.29, respectively.
The AUC I /AUC ratios of 180 possible interactions between the 12 substrates and the 15 inhibitors listed in Table 2 and 3 were calculated (Fig. 1C) . Only a small proportion (21%) of all possible combinations between substrates and inhibitors had been studied in vivo.
Evaluation of the IVIP approach in predicting the DDI risks of various inhibitors with
circulating inhibitory metabolites. The details of the data and calculation are provided as Supplemental Material 1. A total of 14 different combinations of in vivo DDI studies (including 12 inhibitors with inhibitory metabolites) were identified (Table 4) . Two inhibitors (diltiazem and erythromycin) and their metabolites have been shown to possess both reversible and irreversible inhibitory effects on CYP3A (Zhang et al., 2009a) . However, both the reversible and irreversible in vitro models could not accurately predict the AUC ratios (Table 4 ). In general, the predictive performance of the model incorporating unbound hepatic inlet concentration (UHI)
was superior to the model that used total systemic C max (Fig. 2) 
Discussion
There were two primary findings of this study. The first finding is that the modified IVIP approach can be extended to the prediction of CYP2C9-mediated DDIs. For the external validation set, the prediction accuracy for AUC ratios ranged from 70 to 125%. The second finding is that the accuracy of the IVIP approach in predicting DDI risks of 12 inhibitors with circulating inhibitory metabolites was more accurate than in vitro-based methods.
To our knowledge, this is the first proof-of-concept study demonstrating that the IVIP Although the IVIP approach was developed based on previous methods (Ohno et al., 2007; Tod et al., 2011) , some differences merit discussion. In the current study, only the well-known oral and intravenous administration were included in our prediction of CYP2C9-mediated DDIs because the activity of CYP2C9 in the intestine is only 4% of the activity in the liver ).
The IVIP model for CYP2C9-mediated DDIs was also used to forecast the magnitude of a large number of drug interactions that have not been studied. The most potent CYP2C9
inhibitors are predicted to be bucolome and miconazole. Respectively they caused 6.25-, and 6.25-fold increases in the plasma AUC values of the CYP2C9 probe tolbutamide (Fig. 1C) .
According to the FDA classifications of strong, moderate or weak inhibitors (FDA Draft Guidance for Industry, 2012), these perpetrators may be strong inhibitors of CYP2C9. However, no strong inhibitor of CYP2C9 was listed in the new FDA draft guidance and a recent criteriabased assessment of perpetrators (Polasek et al., 2011 (Obach, 2009) . Recently, Shardlow et al. (Shardlow et al., 2011) observed unbound hepatic inlet concentration allowed the accurate prediction of DDIs for the drugs in their dataset (including different types of inhibitors).
Therefore, both total systemic C max and estimates of unbound hepatic inlet concentrations were used as surrogates for the inhibitor concentration in our analysis. Furthermore, in vitro-based models differentiated reversible and irreversible inhibition, and also considered the contribution of intestinal metabolism for CYP3A substrates.
Physiologically based pharmacokinetic (PBPK) approaches to define dynamic perpetrator and victim concentrations are becoming more widespread (Zhao et al., 2011 The limitations of the present study need to be considered. It is noteworthy that the value of IR is dose dependent (as shown in Table 2 ). Because it is estimated from specific in vivo study, and the exposure of the perpetrator has already been considered with the certain relationship with K i or k inact /K I . Therefore, in order to accurately predict a certain clinical DDI, the dose and regimen of the perpetrator in the learning set should not be significantly different from that of the same perpetrator in this clinical DDI study. In addition, in its present form, the IVIP is not applicable to inhibitors that can inhibit both CYP enzymes and transporters such as Pglycoprotein. Failing to account for the interaction with P-glycoprotein may result in under prediction of the AUC ratio. However, our study included an inhibitor (quinidine) that inhibits both CYP2D6 and P-glycoprotein, but no significant under prediction of the AUC ratio was observed. This can be explained by the fact that both victim drugs (desipramine and metoprolol)
in the validation set and learning set are not P-glycoprotein substrates. Further studies are underway in our laboratory to apply the model to transporter-mediated DDIs.
The IVIP approach is validated to be accurate in the prediction of CYP2C9-mediated DDIs and is a useful tool for the prediction of drug interaction risks associated with CYP inhibitors that have circulating inhibitory metabolites. This approach can be used in new drug development after the result of the first clinical DDI study is available.
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